Reducing mobility-related treatment interruptions for people with HIV in Malawi

Reducing Mobility-associated Interruption in HIV Treatment in Malawi (REMIT): Pilot Trial to Assess Acceptability and Feasibility of a Mobility-specific Intervention Package

Not applicable Interventional University of California, Los Angeles · NCT07329166

This pilot tests a package of enhanced counseling, a toll-free helpline, and provider training to help people with HIV in Malawi who travel stay on antiretroviral treatment.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment400 (estimated)
Ages15 Years and up
SexAll
SponsorUniversity of California, Los Angeles Academic / other
Locations1 site (Lilongwe)
Trial IDNCT07329166 on ClinicalTrials.gov

What this trial studies

This pilot uses a cluster-randomized design at six facilities (three intervention, three control) to test a co-created intervention package aimed at reducing mobility-associated interruptions in ART. The package includes enhanced counseling at initiation or re-initiation, a toll-free line for mobile clients and healthcare workers, and trainings to promote multi-month dispensing. Eligible participants (age ≥15) are people living with HIV who are initiating ART or returning to care after missing a refill by 28 days or more; participants complete enrollment surveys and some will have in-depth interviews after six months. The trial will measure feasibility and acceptability among clients and healthcare workers and compare 6-month ART retention between arms to provide a preliminary estimate of efficacy and identify operational barriers to scale-up.

Who should consider this trial

Good fit: People aged 15 or older living with HIV in Malawi who are initiating ART for the first time or returning to care after missing a refill by 28 days or more at participating clinics.

Not a fit: Those attending on behalf of someone else, seeking only an emergency refill, transferring in without a recent interruption, or already stable on routine refills without a recent interruption are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, the intervention could reduce treatment interruptions among mobile people with HIV, improving ART retention and long-term viral suppression.

How similar studies have performed: Enhanced counseling and multi-month dispensing have improved retention in other sub-Saharan African programs, while toll-free helplines and mobility-focused packages have been less widely tested but show promising, mixed results in mobile-support interventions.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. 15 years of age or older
2. Living with HIV
3. Attending ART clinic to initiate OR re-initiate care:

   1. Initiate: initiating ART for the first time, per self-report
   2. Re-initiate: returning to care after missing a refill appointment by \>28 days

Exclusion Criteria:

1. Attending ART clinic on behalf of someone else (i.e. guardian)
2. Attending ART clinic only to obtain emergency refill
3. Attending ART clinic for a routine refill without a recent \>=28 days interruption in treatment
4. Transferring in to study facility without a preceding interruption in treatment of \>=28 days

Where this trial is running

Lilongwe

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions HIVmobilityantiretroviral therapyHIV treatment interruptionART retentionsub-Saharan AfricaMalawiART interruption
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.